Jason M. Broderick

The results of the study are particularly encouraging given the high unmet need for patients with non–clear cell renal cell carcinoma, according to lead investigator Laurence Albiges, MD, PhD.

The findings also showed, however, that the further addition of abiraterone acetate and prednisone to the apalutamide/ADT regimen did not significantly boost clinical outcomes.

The double-blind phase 3 IMmotion010 trial randomized patients with resected renal cell carcinoma at increased risk of recurrence to adjuvant atezolizumab or placebo.

The target of 64Cu SAR-Bombesin is the Gastrin Releasing Peptide receptor, which is found on prostate tumors as well as several other tumors.

"The biggest advantage of this technique is that because the sound waves are coming from inside and going outwards, it doesn't destroy anything beyond the prostate, at least in theory,” said Michael Koch, MD.

“There has never been a clinical trial for these patients. It is unclear whether these patients should be treated with medication, surgery, or another approach. This represents an unmet medical need,” said Raquibul Hannan, MD, PhD.

The ClarityDX Prostate test assesses a combination of clinical and biological biomarker data and provides a risk score that a patient biopsy would show a clinically significant prostate cancer.

The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.

The Avenda system combines the company’s proprietary iQuest AI-based margin prediction software algorithms with its FocalPoint laser ablation device.

The TAVT-45 formulation of abiraterone consists of granules for oral suspension and was created for patients with dysphagia who would have difficulty swallowing a tablet.

The application is supported by findings from the phase 2/3 QUILT-3.032 trial.

The combination induced a response in nearly two-thirds of patients with unresectable locally advanced or metastatic urothelial cancer when used in the frontline setting.

The PROPELLER trial is exploring the novel PSMA-PET imaging product 64Cu-SAR-bisPSMA in patients with treatment-naïve, histologically confirmed prostate cancer who are scheduled for radical prostatectomy

"A significant unmet need remains among long-term care residents with incontinence related to OAB,” said Sef Kurstjens, MD, PhD.

The Centers for Medicare and Medicaid Services is covering the Signatera molecular residual disease test for use in patients with muscle-invasive bladder cancer.

The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with indeterminate renal masses

Exelixis plans to discuss the top level results of the phase 3 COSMIC-313 trial with the FDA regarding a potential application submission for the triplet in this setting.

"Now with FDA approval, patients will have much improved ability to use this efficacious therapy on a long-term basis, which is most beneficial for them," Roger R. Dmochowski, MD, MMHC.

177Lu-PSMA-617 is FDA-approved for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer.

"Too often, men will stay silent about the symptoms they are experiencing from an enlarged prostate that hamper their day-to-day lives," said Dean Elterman, MD.

The FDA decided a New Drug Application lacked sufficient data to approve tebipenem pivoxil hydrobromide (tebipenem HBr) for the treatment of patients with complicated urinary tract infection.

Urology entrepreneurs Neal Patel, MD, and Philip Zhao, MD, proudly tout their handheld, wireless endoscopic camera as a device “designed by urologists for urologists."

“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.

“For clinicians, the analyses show that moderate and severe male LUTS in general are good indicators of poor health," the authors wrote.

Testosterone undecanoate (Tlando), an oral testosterone replacement therapy, was approved in March 2022 for the treatment of men with hypogonadism.

Overall survival was higher among patients with mHSPC who achieved undetectable PSA levels when treated with the triplet of darolutamide, ADT, and docetaxel, according to an analysis from the phase 3 ARASENS trial.

The biomarker analysis used next-generation sequencing to analyze ctDNA and genomic aberrations in 17 prostate cancer–related genes at baseline and at end of study treatment.

"PSMA-PET imaging reports on individual lesions of patients with mCRPC could include SUVmean prior to starting 177Lu-PSMA-617 therapy to provide important prognostic information on potential treatment responses and long-term outcomes," said Andrew J. Armstrong, MD.

The PD-1 inhibitor toripalimab is approved in China for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.

“Cabozantinib plus atezolizumab demonstrated clinical activity with manageable toxicity in inoperable locally advanced or metastatic urothelial carcinoma," said lead author Sumanta K. Pal.